PVLAPalvella Therapeutics, Inc.

1. Aug 4, 2026Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
2. Jul 14, 2026On July 14, 2026, Palvella Therapeutics, Inc. (the “Company”) posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time.Other event · Form 8-K
3. Jun 30, 2026On June 29, 2026 (the “Appointment Date”), the Board of Directors (the “Board”) of Palvella Therapeutics, Inc. (the “Company”) increased the size of the Board from seven to eight members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Matthew Pauls, to serve as a Class I …Director or officer change · Form 8-K
4. Jun 16, 2026On June 10, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Palvella Therapeutics, Inc. (the “Company”), the Company’s stockholders approved the amendment (the “Plan Amendment”) to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan to increase the authorized shares issuable …Director or officer change · Form 8-K
5. May 20, 2026On May 20, 2026, Palvella Therapeutics, Inc. (the “Company”) issued a press release announcing that new positive clinical data and findings from the Company’s Phase 3 SELVA and Phase 2 TOIVA studies were reported at the International Society for the Study of Vascular Anomalies World Congress 2026.Other event · Form 8-K
6. May 15, 2026On May 15, 2026, Palvella Therapeutics, Inc. (the “Company”) issued a press release announcing that new data from the Company’s Phase 2 TOIVA trial of QTORIN™ rapamycin in patients with cutaneous venous malformations were presented at the 83rd Annual Meeting of the Society for Investigative Dermatology.Other event · Form 8-K
7. May 13, 2026On May 11, 2026, Palvella Therapeutics, Inc. (the “Company”) received approval from the Nasdaq Listing Qualifications Department to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effective with the open of business on May 13, 2026.Other event · Form 8-K
8. May 7, 2026Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
9. Apr 13, 2026On April 13, 2026 (the “Appointment Date”), the Board of Directors (the “Board”) of Palvella Therapeutics, Inc. (the “Company”) increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed John Doux, M.D., to serve as a Class III …Director or officer change · Form 8-K
10. Apr 7, 2026On April 7, 2026, Palvella Therapeutics, Inc. (the “Company”) posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time.Other event · Form 8-K
11. Mar 31, 2026Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update.Earnings release · press release
12. Feb 26, 2026On February 25, 2026, Palvella Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters listed in Schedule A …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.